News

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...
Despite the indication of a potential risk, people who receive abnormal results on blood-based colorectal screening tests commonly do not receive the follow-up colonoscopy.
The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...
A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...
Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...
James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...
James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...